Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Orna NitzanWalid Saliba

Abstract

Urinary tract infections are more common, more severe, and carry worse outcomes in patients with type 2 diabetes mellitus. They are also more often caused by resistant pathogens. Various impairments in the immune system, poor metabolic control, and incomplete bladder emptying due to autonomic neuropathy may all contribute to the enhanced risk of urinary tract infections in these patients. The new anti-diabetic sodium glucose cotransporter 2 inhibitors have not been found to significantly increase the risk of symptomatic urinary tract infections. Symptoms of urinary tract infection are similar to patients without diabetes, though some patients with diabetic neuropathy may have altered clinical signs. Treatment depends on several factors, including: presence of symptoms, severity of systemic symptoms, if infection is localized in the bladder or also involves the kidney, presence of urologic abnormalities, accompanying metabolic alterations, and renal function. There is no indication to treat diabetic patients with asymptomatic bacteriuria. Further studies are needed to improve the treatment of patients with type 2 diabetes and urinary tract infections.

Citations

Apr 22, 2016·Jundishapur Journal of Microbiology·Kimia SeifiHamidreza Houri
Feb 24, 2016·Indian Journal of Endocrinology and Metabolism·Mathew JohnRejitha Jagesh
Oct 3, 2017·Biomédica : revista del Instituto Nacional de Salud·Laura Cristina Nocua-BáezBetsy Castro-Cardozo
Nov 2, 2019·Journal of General Internal Medicine·Radhika RastogiMichael B Rothberg
Jan 12, 2020·Journal of Basic and Clinical Physiology and Pharmacology·Budi SupraptiCahyo Wibisono
Jun 30, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anil MorReimar W Thomsen
Aug 28, 2015·The Journal of Clinical Endocrinology and Metabolism·Kristian Hallundbæk MikkelsenAnton Pottegård
Aug 15, 2020·Frontiers in Immunology·Gholamreza DaryaborKurosh Kalantar
Oct 24, 2019·BioMed Research International·Sunayana RayaNabin Kishor Bimali
Aug 13, 2020·Curēus·Syed Muhammad Jawad ZaidiSyed Faheem Bukhari
Oct 13, 2017·Pakistan Journal of Biological Sciences : PJBS·Ali Al-AsoufiKhaled Khleifat
Apr 24, 2020·MSphere·Kathryn A PatrasVictor Nizet
Mar 30, 2020·World Journal of Urology·Guohua ZengAyberk Bayramgil
Jul 30, 2020·International Journal of Microbiology·Vincent M MagetoWachuka G Njoroge
Dec 20, 2020·International Journal of Environmental Research and Public Health·Ana López-de-AndrésRodrigo Jiménez-García
Mar 6, 2021·Frontiers in Public Health·Jesús Chávez-ReyesBruno A Marichal-Cancino
May 8, 2021·Life Science Alliance·Tahmineh EbrahimzadehNicole J De Nisco
Aug 21, 2021·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Josh ReedVenkateswarlu Kanamarlapudi
Aug 27, 2021·Frontiers in Surgery·Johnathan A KhusidMantu Gupta
Sep 8, 2021·MBio·Panatda Saenkham-HuntsingerSargurunathan Subashchandrabose

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

© 2022 Meta ULC. All rights reserved